

=> d bib abs hitstr 132 6

~~132~~ ANSWER 6 OF 37 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1999:262172 HCAPLUS  
 DN 130:306613

TI Cytokine production blockers for the management of uterine contractions

IN Alvi, Samir Ahmed

PA Imperial College Innovations Ltd., UK

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9918942	A1	19990422	WO 1998-GB3015	19981008
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,				

TM	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
----	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--

	AU 9894493	A1	19990503	AU 1998-94493	19981008
--	------------	----	----------	---------------	----------

PRAI US 1997-61614 19971010  
 WO 1998-GB3015 19981008

OS MARPAT 130:306613

AB The present invention is to the novel use of a cytokine inhibitor for the prophylactic treatment, or management of excessive, undesired or inappropriate uterine activity, such as contractions, in a mammal in need thereof. An example of a cytokine-prodn. blocker is SKF 86002 [6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo[2,1-b]thiazole], a CSBP/p38 protein kinase RK inhibitor.


IT 165806-61-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (cytokine prodn. blockers for the management of uterine contractions)

RN 165806-61-1 HCAPLUS

CN Quinoline,



4-[4-(4-fluorophenyl)-1-[3-(4-morpholinyl)propyl]-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 132 7

L32 ANSWER 7 OF 37 HCAPLUS COPYRIGHT 2000 ACS  
 AN 1998:789144 HCAPLUS  
 DN 130:38377  
 TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors  
 IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce  
 Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Hanson, Gunnar J.;  
 Koszyk, Francis J.; Liao, Shuyuan; Partis, Richard A.; Rao, Shashidhar  
 N.: Seiness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Weier,  
 Richard  
 M.; Xu, Xiangdong; et al.  
 PA G.D. Searle and Co., USA; et al.  
 SO PCT Int. Appl., 828 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9852940	A1	19981126	WO 1998-US10436	19980522
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9875883	A1	19981211	AU 1998-75883	19980522
PRAI	US 1997-47570		19970522		
	WO 1998-US10436		19980522		
OS	MARPAT	130:38377			
GI					



AB Title compds. [I; R1 = H, NH<sub>2</sub>, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 =  
 H, halo, alkyl, alkoxy, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 =  
 H, alkyl, heterocyclyl, aryl, etc.] were prep'd. Thus, R<sub>3</sub>CH<sub>2</sub>COMe (R<sub>3</sub> =  
 4-pyridinyl) was condensed with 3,4-F(MeO)C<sub>6</sub>H<sub>3</sub>CHO and the product  
 Searched by John Dantzman 308-4488

cyclocondensed with TsNNNH<sub>2</sub> to give title compd. II. Data for biol. activity of I were given.


IT 216507-23-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heteroarylpyrazoles as p38 kinase inhibitors)

RN 216507-23-2 HCPLUS

CN Quinoline, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 132 9

L32 ANSWER 9 OF 37 HCPLUS COPYRIGHT 2000 ACS  
AN 1998:709894 HCPLUS  
DN 130:90069  
TI Pyrroles and other heterocycles as inhibitors of p38 kinase  
AU de Laszlo, Stephen E.; Visco, Denise; Agarwal, Lily; Chang, Linda; Chin,  
Jayne; Croft, Gist; Forsyth, Amy; Fletcher, Daniel; Frantz, Betsy;  
Hacker,  
Candice; Hanlon, William; Harper, Coral; Kostura, Matthew; Li, Bing;  
Luell, Sylvie; MacCoss, Malcolm; Mantlo, Nathan; O'Neill, Edward A.;  
Orevillo, Chad; Pang, Margaret; Parsons, Janey; Rolando, Anna; Sahly,  
Yousif; Sidler, Kelley; Widmer, W. Rick; O'Keefe, Stephen J.  
CS Departments of Medicinal Chemistry, Inflammation Research and  
Pharmacology, Merck Research Laboratories, Rahway, NJ, 07065, USA  
SO Bioorg. Med. Chem. Lett. (1998), 8(19), 2689-2694  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
AB Investigation of furans, pyrroles and pyrazolones identified  
3-pyridyl-2,5-diarylpyrroles as potent, orally bioavailable inhibitors of  
p38 kinase. 3-(4-pyridyl-2-(4-fluoro-phenyl))-5-(4-  
methylsulfinylphenyl)pyrrole (L-167307) reduces secondary paw swelling in  
the rat adjuvant arthritis model: ID50= 7.4 mg/kg/b.i.d.  
IT 188352-47-8  
RL: BAC (Biological activity or effector, except adverse); BIOL  
(Biological study)  
(prepn. and structure activity relations of heterocyclic p38  
kinase inhibitors)  
RN 188352-47-8 HCPLUS  
CN Quinoline,  
4-[2-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-1H-pyrrol-3-  
yl]- (9CI) (CA INDEX NAME)

